Chemical Biology Program
The Yael David Lab
Research efforts in the David lab apply core techniques in chemical biology, biochemistry, and cell biology to address fundamental questions in the epigenetic regulation of transcription. Epigenetic regulation relies on the dynamic modification of the two building blocks of chromatin: DNA and histone packaging proteins, to establish and maintain cell identity and fate. We develop and utilize chemical methods to synthesize site-specifically modified histones in vitro and in vivo and study the roles that these modifications play in disease states, with the ultimate goal of targeting them for therapeutics.
Zheng Q, Omans ND, Leicher R, Osunsade A, Agustinus AS, Finkin-Groner E, D’Ambrosio H, Liu B, Chandarlapaty S, Liu S, David Y. Reversible histone glycation is associated with disease-related changes in chromatin architecture. Nat Commun. 2019 Mar 20;10(1):1289. doi: 10.1038/s41467-019-09192-z
Osunsade A, Prescott NA, Hebert JM, Ray DM and David Y. A Robust Method for the Purification and Characterization of the Human Histone H1 Variants. Biochemistry. 2018 Dec 26. doi: 10.1021/acs.biochem.8b01060.
Yael David, PhD
- Yael David’s lab develops and applies methods in chemical biology toward studying epigenetic regulation and its correlation with disease states.
- Ph.D – The Weizmann Institute of Science
- B.Sc SUNY Stony Brook
- Josie Robertson Investigator (2016-2021)
- Pershing Square Sohn Cancer Alliance Award
- Experimental Therapeutic Discovery Center grant
- Specialized Program of Research Excellence (SPORE) Award
- CEBRA award
- Parker Institute for Cancer Immunotherapy Award
- Star Cancer Consortium grant
- The Center for Educational Resources Project Collaborative Grant
- National Institute of General Medical Sciences grant
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Yael David discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.